Puerto Rico Puerto Rico’s healthcare system is a paradox of strength and fragility. With one of the highest insurance coverage rates in the US (around 94 percent) and a long tradition of medical excellence, it has also faced persistent funding gaps and a growing exodus of talent. Now, new federal policy shifts…

France France is experiencing its biggest pharmaceutical manufacturing boom in decades, with global giants like Novo Nordisk, Sanofi, and Pfizer committing over EUR 4 billion in new investments since 2023. This wave of capital represents more than just expansion – it signals a broader pivot toward European pharmaceutical independence and potentially…

Belgium The latest stories from healthcare and the life sciences in Belgium, the Netherlands and Luxembourg (BeNeLux). UCB is considering a USD five billion investment in the US to avoid President Trump’s tariffs on the EU; Belgium’s competition authority fines three consumer healthcare companies; and the launch of a EUR 200…

Europe For over two decades, Europe’s pharmaceutical manufacturing footprint has steadily shifted offshore towards countries like China and India, driven by the pursuit of lower costs and operational efficiencies. However, the COVID-19 pandemic, coupled with growing geopolitical instability and increasing complexity in modern therapies, has exposed the risks of this model.…

LatAm Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD 560 million; a worrying new report from the Pan-American Health Organisation showing that measles cases are up 29-fold in the…

Hong Kong With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city, with its unique background context and characteristics, to play a role shaping the next wave of biomedicine discovery.   Dr…

Hong Kong At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper, however, and its distinctive and differentiated offering becomes ever more apparent.    “While Hong Kong’s biomedical ecosystem certainly still lags…

Hong Kong In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team of clinicians and scientists at the Chinese University of Hong Kong (CUHK), Prince of Wales Hospital, and the Hong Kong…

Hong Kong Hong Kong has a burgeoning status within Greater China as an advanced therapy hub. The Special Administrative Region boasts clinical trial expertise, internationally aligned regulation, a lack of price caps, and the recently minted ability to produce cell and gene therapies within the city. This means that, today, more new…

Hong Kong Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent magnet.’ From a professional standpoint, the city’s international connectivity, financial architecture, and efficient infrastructure already render it an appealing location…

Europe As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals and experienced regulators, it has struggled with a complicated and fragmented approval system that has pushed trial sponsors elsewhere. To…

MEA A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines; Jordan’s Hikma makes a USD 1 billion investment pledge for US manufacturing and R&D, and Riyadh-headquartered private equity firm Jadwa…